PTCT files 8-K on Q3 2025 results; Exhibit 99.1 furnished

Rhea-AI Filing Summary

PTC Therapeutics filed an 8-K announcing financial results for the quarter ended September 30, 2025. The full details are provided in a press release furnished as Exhibit 99.1.

The company will host a conference call on November 4, 2025 at 4:30 p.m. Eastern to review the results and other updates. Items 2.02 and 7.01, and Exhibit 99.1, are furnished and not deemed filed under Section 18 of the Exchange Act.

0001070081false00010700812025-11-042025-11-04

​

​

UNITED STATES

​

SECURITIES AND EXCHANGE COMMISSION

​

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 4, 2025

​

PTC THERAPEUTICS, INC.

​

(Exact Name of Company as Specified in Charter)

​

​	​	​	​	​
Delaware		001-35969		04-3416587
(State or Other Jurisdiction	​	(Commission	​	(IRS Employer
of Incorporation)	​	File Number)	​	Identification No.)

​

​

​	​	​	​
500 Warren Corporate Center Drive	​		​
Warren, NJ	​	​	07059
(Address of Principal Executive Offices)	​	​	(Zip Code)

​

Registrant’s telephone number, including area code: (908) 222-7000

​

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share	​	PTCT	​	Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2025, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference into this Item 2.02.

Item 7.01. Regulation FD Disclosure.

The Company will host a conference call on November 4, 2025, at 4:30 p.m. eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended September 30, 2025, as well as other corporate highlights and updates. Instructions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.

​

The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

​	​	​
Exhibit No.		Description
99.1	​	Press Release, dated November 4, 2025 issued by PTC Therapeutics, Inc.
104	​	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

​

​

​

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	PTC Therapeutics, Inc.
​	​
Date: November 4, 2025	By:	/s/ Pierre Gravier
​	Name:	Pierre Gravier
​	Title:	Chief Financial Officer

​

​

FAQ

What did PTCT announce in its 8-K?

PTC Therapeutics announced financial results for the quarter ended September 30, 2025, with details furnished in Exhibit 99.1.

When is PTC Therapeutics’ conference call for Q3 2025?

The company will host a conference call on November 4, 2025 at 4:30 p.m. ET.

Where can I find the full Q3 2025 results for PTCT?

The full text is in the press release furnished as Exhibit 99.1 to the 8-K.

Are the Items 2.02 and 7.01 considered filed?

No. The 8-K states Items 2.02 and 7.01, and Exhibit 99.1, are furnished and not deemed filed under Section 18 of the Exchange Act.

What exchange and ticker does PTC Therapeutics trade under?

PTC Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol PTCT.

Who signed the 8-K for PTCT?

The report was signed by Pierre Gravier, Chief Financial Officer.